...
首页> 外文期刊>Molecular cancer therapeutics >Astrocyte elevated gene-1: a novel target for human glioma therapy.
【24h】

Astrocyte elevated gene-1: a novel target for human glioma therapy.

机译:星形胶质细胞升高基因1:人类神经胶质瘤治疗的新目标。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Malignant gliomas including glioblastoma multiforme (GBM) and anaplastic astrocytomas are the most common primary brain tumors. Despite multimodal treatment including surgery, chemotherapy, and radiation, median survival for patients with GBMs is only 12 to 15 months. Identifying molecules critical for glioma progression is crucial for devising effective targeted therapy. In the present study, we investigated the potential contribution of astrocyte elevated gene-1 (AEG-1) in gliomagenesis and explored the possibility of AEG-1 as a therapeutic target for malignant glioma. We analyzed the expression levels of AEG-1 in 9 normal brain tissues and 98 brain tumor patient samples by Western blot analysis and immunohistochemistry. AEG-1 expression was significantly elevated in >90% of diverse human brain tumor samples including GBMs and astrocytic tumors, and also in human glioma cell lines compared with normal brain tissues and normal astrocytes. Knockdown of AEG-1 by small interfering RNA inhibited cell viability, cloning efficiency, and invasive ability of U87 human glioma cells and 9L rat gliosarcoma cells. We also found that matrix metalloproteases (MMP-2 and MMP-9) are involved in AEG-1-mediated invasion of glioma cells. In an orthotopic nude mouse brain tumor model using primary human GBM12 tumor cells, AEG-1 small interfering RNA significantly suppressed glioma cell growth in vivo. Taken together, these provocative results indicate that AEG-1 may play a crucial role in the pathogenesis of glioma and that AEG-1 could represent a viable potential target for malignant glioma therapy.
机译:恶性神经胶质瘤包括多形胶质母细胞瘤(GBM)和间变性星形细胞瘤是最常见的原发性脑肿瘤。尽管采取了包括外科手术,化学疗法和放射线在内的多模式治疗,GBM患者的中位生存期仅为12至15个月。鉴定对神经胶质瘤进展至关重要的分子对于设计有效的靶向治疗至关重要。在本研究中,我们调查了星形胶质细胞升高基因1(AEG-1)在神经胶质瘤发生中的潜在作用,并探讨了AEG-1作为恶性神经胶质瘤治疗靶标的可能性。我们通过蛋白质印迹分析和免疫组化分析了9例正常脑组织和98例脑肿瘤患者样品中AEG-1的表达水平。与正常的脑组织和正常的星形胶质细胞相比,在包括GBM和星形胶质细胞瘤在内的各种人类脑肿瘤样品中,> 90%的AEG-1表达均显着升高。通过小的干扰RNA抑制AEG-1抑制了U87人神经胶质瘤细胞和9L大鼠神经胶质瘤细胞的细胞活力,克隆效率和侵袭能力。我们还发现基质金属蛋白酶(MMP-2和MMP-9)参与了AEG-1介导的胶质瘤细胞的侵袭。在使用原代人GBM12肿瘤细胞的原位裸鼠脑肿瘤模型中,AEG-1小干扰RNA显着抑制了体内神经胶质瘤细胞的生长。综上所述,这些令人鼓舞的结果表明,AEG-1可能在神经胶质瘤的发病机理中起着至关重要的作用,而AEG-1可能代表了恶性神经胶质瘤治疗的可行潜在靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号